Median plasma levels of IFN-α2 (174.27 vs. 199.64 pg/mL, p<0.008); IL-1Ra (418.73 vs. 503.33 pg/mL, p<0.02) and IL-16 (1931.86 vs. 3535.39 pg/mL, p<0.0001) were all significantly lower in early breast cancer patients compared to healthy controls. This evidence concerns the gene IFNA2 and breast cancer.